IDH2 and acute myeloid leukemia: IDH2 mutations occur in ~12–15% of patients with AML [9], with higher frequencies in older patients; mutation analyses in a subgroup of patients aged ≥65 years with newly diagnosed AML in a phase III study of azacitidine showed 23% of patients had an IDH2 mutation at study entry [10].